Scholarlink

Purpose <p>Despite Phosphoenolpyruvate carboxykinase 2 (PCK2) has attracted growing attention as a potential biomarker in cancer research, its role in medulloblastoma (MB) remains unclear. This research aims to evaluate PCK2 as a novel biomarker for groups 3 and 4&#xa0;MB and to investigate its associations with prognosis and the tumor immune microenvironment.</p> Methods <p>Five cohorts were extracted to identify characteristic genes associated with MB molecular subtypes through gene differential expression analysis and machine learning techniques. Kaplan-Meier survival analysis, alongside univariate and multivariate COX regression analyses, was employed to investigate the relationship between <i>PCK2</i> expression and clinical significance. Immunohistochemistry was used to detect <i>PCK2</i> expression in MB samples. ROC analysis was performed to verify the specificity of <i>PCK2</i>. MCP-counter, CIBERSORT, and ssGSEA were used to explore the correlation of tumor-infiltrating immune cells according to <i>PCK2</i> expression. Immunofluorescence was performed to testify the co-expression patterns across PCK2, CD206 and PD-L1 in MB tissues.</p> Results <p><i>PCK2</i> is increasingly expressed in Group 3&#xa0;MB and could serve as an independent poor prognostic indicator for MB patients. <i>PCK2</i> correlates with immune infiltrates and immunosuppression. Furthermore, <i>PCK2</i> exhibits a positive correlation with M2-type macrophage infiltration and is co-expressed with CD206 and PD-L1 in MB tissues.</p> Conclusion <p>Our study demonstrates that PCK2 may serve as a reliable biomarker for differentiating Group 3 from Group 4&#xa0;MB and could potentially play a role in immunotherapy-related mechanisms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phosphoenolpyruvate carboxykinase 2 as a prognostic biomarker: expression and clinical significance in Group 3 and Group 4 medulloblastoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月25日

查看全文
  • Shiqi Zheng,
  • Long Lin,
  • Guotao Ren,
  • Hangzhu Lan,
  • Yingying Pan,
  • Meng Zhang,
  • Wenbin Guan,
  • Ruifen Wang,
  • Lifeng Wang

摘要

Purpose

Despite Phosphoenolpyruvate carboxykinase 2 (PCK2) has attracted growing attention as a potential biomarker in cancer research, its role in medulloblastoma (MB) remains unclear. This research aims to evaluate PCK2 as a novel biomarker for groups 3 and 4 MB and to investigate its associations with prognosis and the tumor immune microenvironment.

Methods

Five cohorts were extracted to identify characteristic genes associated with MB molecular subtypes through gene differential expression analysis and machine learning techniques. Kaplan-Meier survival analysis, alongside univariate and multivariate COX regression analyses, was employed to investigate the relationship between PCK2 expression and clinical significance. Immunohistochemistry was used to detect PCK2 expression in MB samples. ROC analysis was performed to verify the specificity of PCK2. MCP-counter, CIBERSORT, and ssGSEA were used to explore the correlation of tumor-infiltrating immune cells according to PCK2 expression. Immunofluorescence was performed to testify the co-expression patterns across PCK2, CD206 and PD-L1 in MB tissues.

Results

PCK2 is increasingly expressed in Group 3 MB and could serve as an independent poor prognostic indicator for MB patients. PCK2 correlates with immune infiltrates and immunosuppression. Furthermore, PCK2 exhibits a positive correlation with M2-type macrophage infiltration and is co-expressed with CD206 and PD-L1 in MB tissues.

Conclusion

Our study demonstrates that PCK2 may serve as a reliable biomarker for differentiating Group 3 from Group 4 MB and could potentially play a role in immunotherapy-related mechanisms.